Monday, November 17, 2025
HomeTagsCtDNA

Tag: ctDNA

Healthcare

Tempus Announces the Clinical Launch of its MRD Testing Portfolio

xM MRD and NeXT Personal Dx tests are now available for physicians in the U.S. for early cancer recurrence detection and residual disease monitoring Tempus,...
Healthcare

Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only

Tempus, a leader in artificial intelligence and precision medicine, announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions. The...
Healthcare

Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

Pan-cancer study showed MTM/mL dynamics were more predictive of therapy response than mVAF dynamics, with an observed hazard ratio nearly 2x higher Natera, Inc., a...
Healthcare

Tempus Announces New ctDNA Assay, xF Monitor

Tempus, a leader in artificial intelligence and precision medicine, announced xF Monitor – a new circulating tumor DNA (ctDNA) assay for research use only,...

Recent Published

About Us

Discover the future of artificial intelligence at AITech365. Explore the latest AI news, delve into insightful interviews with industry experts, and stay informed about the most exciting and trending topics shaping the world of AI.

Latest

Popular

Quick Link

© 2025 AITech365. All Rights Reserved. Website Undertaking: Data Demand